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Task Force 7. Evaluation and Management of Risk Factors for the 
Individual Patient (Case Management) 
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THOMAS B. GRABOYS, MD, FACC, DANIEL J. ULLYOT, MD, FACC 
Several factors that increase risk for atherosclerosis n general, 
and coronary disease in particular, have been identified and 
are generally accepted in medical practice as valid and relevant 
(1). These include cigarette smoking, sedentary life-style, 
hypertension, abnormal blood lipid levels and a thrombogenic 
tendency, among others. However, conclusive evidence from 
population-based studies of reduction of all-cause mortality by 
modification of such risk factors has been lacking (2-4). 
Nevertheless, ignificant (although modest) reduction in coro- 
nary artery disease (CAD) mortality and morbidity has been 
found in these population studies. This benefit is greatest in 
patients with evidence of coronary disease, or in studies in 
which the control subjects are at a mortality risk of 4% or 
greater per year (5,6). 
The term prevention--"primary" or "secondary"--is widely 
used to encompass reduction of these common risk factors in 
normal persons or in patients with coronary heart disease, 
respectively. "Primary prevention" implies becoming a non- 
smoker, maintaining a normal blood pressure and a desirable 
body weight and consuming no more than 10% of calories 
from saturated fat. In these healthy people, behavior modifi- 
cation, diet and exercise programs are designed to promote a 
healthy life-style. Also, these measures will allow some people 
to avoid or delay the development of atherosclerosis. "Second- 
ary prevention" relates to the treatment of coronary artery 
disease in patients who have had a clinical event (for example, 
angina pectoris or acute myocardial infarction) by reduction of 
conventional risk factors but also includes the use of cardio- 
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Table 1. Priorities of Coronary Heart Disease Prevention i  
Clinical Practice 
1. Patients with established CHD or other atherosclerotic vascular disease 
2. Asymptomatic subjects with particularly high risk (subjects with severe 
hypercholesterolemia or other forms of dyslipidemia, diabetes or
hypertension; subjects with a cluster of several risk factors) 
3. Close relatives ofpatients with early-onset CHD or other atherosclerotic 
vascular disease; asymptomatic subjects with particularly high risk 
4. Other subjects met in connection with ordinary clinical practice 
CHD = coronary heart disease. 
active, vasoactive, lipid-lowering and other drugs. Clearly, this 
activity properly belongs within the more formal structure of 
clinical practice. The designation of this activity as "preven- 
tion" is misleading (7,8) and a preferable description would be 
"the medical management of coronary atherosclerosis." As a 
practical matter, "preventive" care services may not be com- 
pensated in many insurance and managed care programs. 
Further, the qualifier "secondary" carries an implication of 
lesser importance to patient and provider. Hence, although 
these terms have been established by epidemiologic conven- 
tion, we prefer the designation "optimal medical manage- 
ment" in this task force report. 
The Patient With Coronary Artery Disease 
Atherosclerosis a complex polygenic, multifactorial vas- 
cular disorder associated with many differing and changing 
metabolic, anatomic and clinical manifestations (9). Two 
markedly differing eneral mechanisms--instability of he cor- 
onary artery wall in an area of nonobstructive atherosclerosis, 
and the severity of vascular obstruction locally or in sum--are 
responsible for ischemic symptoms and adverse vents (10,11). 
Instability of the coronary endothelial surface is associated 
with the inflammatory reaction, the lipid content of the 
atherosclerotic plaque, the state and thickness of the fibrous 
cap, local fluid dynamics and vasomotion, as well as with lipid 
levels. Readily definable characteristics other than a prior 
coronary event also place other subjects at high risk (Table 1). 
These groups include individuals with familial hypercholester- 
olemias, a strong family history of premature coronary artery 
disease, diabetes mellitus, other lipid profile abnormalities, 
hypertension, obesity and adverse behavior practices, such as 
excessive cigarette smoking alone or in combination. In these 
subjects, the probability of adverse vents, including myocar- 
dial infarction, is great. In patients with coronary disease, risk 
factor modification has proved to be of benefit in regard to 
all-cause mortality and cardiovascular mortality and morbidity, 
and in several recent studies the reduction i  disease and death 
is of a sufficient magnitude to be important o individual 
patients over a relatively short ime. This may reflect improved 
endothelial cell function, plaque stabilization and altered 
coagulation--alone or in combination. Major or minor genetic 
traits, abnormalities of vascular biology, hemostasis and glu- 
cose intolerance, among others, interrelate in a complex 
manner. The detailed management of dyslipidemias in at-risk 
patients requires a thorough understanding of these interrela- 
tionships and of the clinical pharmacology of lipid-lowering 
drugs. Thus, treatment s rategies may differ importantly be- 
tween individual patients, and mandate a high standard of 
physician knowledge, skill, motivation and performance. 
Patients with clinical angina pectoris have a high probability 
of an obstruction of at least one major coronary artery. While 
those who have sustained an infarction have demonstrated a 
propensity to thrombosis, all patients with coronary artery 
disease and those with an adverse coronary profile are at 
increased risk for further adverse outcomes. Risk factor mod- 
ifications favorably affect several processes central to athero- 
genesis and thrombosis. Serum fibrinogen, a powerful predic- 
tor of coronary events (12), is now undergoing study. Future 
research will serve to define the details of adverse platelet 
function, fibrinogen and antifibrins, plasminogen activators 
and inhibitors, the trigger role of the autonomic nervous 
system (13), the composition of the vessel wall and the 
reactions of the coronary endothelial surface. Risk factors, 
known and unknown, and their interaction one with the other 
are sufficiently complex as to require special expertise in their 
analysis and details of management. In the future, as these 
matters are resolved, the therapeutic strategies will change 
'dramatically, and will prove to be more specific, effective and 
efficient. 
The prognosis of established coronary artery disease ap- 
pears to be improving. This in turn exerts an impact on the 
predictive accuracy of current measures of risk stratification. 
New demographic information, and more sensitive noninvasive 
and invasive testing methods, are now available. Although 
extrapolation from older data bases may not be ideal, it will 
have to suffice until new data bases are available. Despite these 
favorable trends in prognosis, it is now clear that effective 
management of common risk factors in patients with coronary 
artery disease will result in further improvement in the fre- 
quency and severity of subsequent coronary events. 
The Current Dilemma 
Despite the scientific evidence for the significance of com- 
mon risk factors on outcomes and the availability of effective 
remedies, the ongoing long-term edical management of the 
patient with coronary disease remains fragmented and is often 
unsatisfactory (8). Patients with coronary disease receive their 
care from both general physicians and cardiovascular special- 
ists. The latter usually participate in the acute management of 
unstable angina pectoris and myocardial infarction, perform 
diagnostic testing and participate in invasive revascularization 
procedures. The former are concerned primarily with longer 
term medical management i  the clinically quiescent phase. 
Despite the overwhelming evidence as to benefit, effective risk 
reduction strategies are not consistently pursued (14,15). In 
many instances, cardiovascular specialists are best positioned 
to direct the patient with coronary disease in or into a 
long-term anagement plan, yet fail to do so. Many general 
physicians and some cardiovascular specialists do not seem to 
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be aware that patient benefit requires apatient-specific plan, a 
regular follow-up to ensure attainment of specific goals, mod- 
ification of goals and treatment strategies when necessary and 
a lifelong commitment. Both general physicians and cardiovas- 
cular specialists require careful initial and continuing medical 
education in the evaluation and management of risk factors in 
the patient with coronary disease. 
The Objective 
Recognizing that cardiovascular disease management re- 
quires insights into the entire spectrum of disease manifesta- 
tions from initiation through quiescence to acute illness, a 
commitment now to reducing adverse outcomes by favorably 
altering risk factors is crucial. The objectives of risk reduction 
strategies are to reduce all-cause and cardiovascular mortality, 
ischemic symptoms, myocardial infarction, arrhythmias, heart 
failure, other manifestations of atherosclerosis and to improve 
general health. Although benefit in the elderly has been 
questioned (16), evidence for benefit of risk factor eduction in 
other patient groups is overwhelming (17-21). 
Implementation 
Whether in the acute or quiescent phase of cardiovascular 
disease, effective and efficient management requires a well 
founded clinical strategy described in a clear protocol and an 
integrated health care delivery system, as, for example, in 
approaches to the emergent management of the patient with 
new-onset chest pain. Within such a system, which aligns the 
patient with physicians, other health care personnel and the 
insurer, positive incentives are necessary so that the necessary 
attention is directed to risk stratification and effective risk 
reduction. A "system" may be implemented by solo practitio- 
ners, small group practices, hospital-based or other clinics, as 
well as by large providers, as, for example, managed care 
organizations or the Department of Veterans Affairs. System 
implies the organizational structure necessary toimplement an 
effective, efficient management protocol using resources avail- 
able and appropriate to patient need. For example, a trained 
nurse practitioner working closely with a motivated primary 
care physician might require advice from an independent 
qualified dietitian from time to time, whereas a large clinic 
ould employ such personnel. Likewise, a general internist might 
have an arrangement for periodic review by a cardiovascular 
specialist to implement an improved evaluation and new treat- 
ment approaches, including drug therapy. In other circumstances 
a larger organization would provide comprehensive in-house 
cardiology services. The cardiovascular specialist is also qualified 
to provide the necessary expertise in the direct management of
the acute coronary syndromes and their complications. 
The Clinical Strategy 
The clinical strategy requires a specific protocol to clarify 
logistic issues and responsibilities. Risk factor assessment and 
current cardiac status (the necessary data sets for initial 
evaluation and regular follow-up) and further invasive or 
noninvasive testing are among the clinical matters to be 
implemented. Goals for blood pressure, blood lipids, nutrition, 
physical activity and stress levels are required for patient 
education and behavior modification. Knowledge of the ef- 
fects, side effects, dosing protocols and monitoring of drugs 
used to control blood pressure, reduce lipids and modify 
coagulation processes must be available. 
Such a strategy mandates the development of a long-term 
program that includes an initial risk assessment (including the 
impact of existing cardiac or other disease), a specific treat- 
ment plan and an outcomes-based long-term assessment for 
each patient as an individual, and an effective follow-up for 
compliance. Specially trained physicians (e.g., cardiologists, 
internists and family practitioners) must attain those qualifica- 
tions necessary to provide the expertise and direction in risk 
assessment and long-term management of patients with car- 
diovascular disease (22). It is mandatory for physicians who 
take such leadership responsibilities tobecome knowledgeable 
of the basic relations of lipids, hemostatic and other factors 
related to atherosclerosis and vascular stability. These respon- 
sible physicians must design and, if necessary, modify the 
details of long-term management, even when it is to be de- 
livered by other health care providers. Expert ongoing review 
is required as new information emerges to ensure that man- 
agement strategies continue to correct or favorably modify risk 
factors, particularly at times when untoward events occur. The 
concept hat an appropriate l vel of care can be provided by 
health care personnel with a minimal understanding of these 
complex processes i naive, and could prove inadequate for 
many individual patients. 
Initial Evaluation 
Each patient determined to have or to be at risk for 
coronary artery disease will require an individualized evalua- 
tion and an identification of the contribution of the various 
metabolic, hemostatic, hormonal and autonomic nervous ys- 
tem elements contributing to that risk. Low socioeconomic 
status must also be taken into account as an important 
predictor of cardiovascular risk. In addition to a careful 
medical history and physical examination, a detailed patient 
summary is required regarding coronary disease and death in 
kindred, and accurate blood pressure, body weight and height 
measurements. A 12-lead electrocardiogram is necessary. Lab- 
oratory studies must include at least one fasting lipid 
profile, including total cholesterol, high density lipoprotein 
(HDL) cholesterol, total/HDL cholesterol ratio, triglycerides, 
calculated low density lipoprotein (LDL) cholesterol and 
fasting blood glucose values (Fig. 1). Isolated total serum 
cholesterol values alone may be misleading. In the future, other 
laboratory studies, including lipoprotein(a), fibrinogen and 
ferritin levels as well as genetic markers may refine even 
more accurately the establishment of individual risk. When 
appropriate, functional stress testing is useful to define physi- 
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Figure 1. Initial risk appraisal. CABG = cor- 
onary artery bypass graft surgery; HDL = 
high density lipoprotein cholesterol; LDL = 
low density lipoprotein cholesterol; MI = 
myocardial infarction; PTCA = percutaneous 
transluminal coronary angioplasty; VD = 
vessel disease; VF = ventricular fibrillation; 
VT = ventricular tachycardia. 
Risk Elements 
Age • Gender 
History of Preventive Coronary Disease in a First-Degree Relative? (Male <55 years; female 
<65 years) Yes ; No 
Socioeconomic status? Low 
Weight, Height? 
Total Cholesterol, _ _  
• Not Low__  
Ibs.' ' "(ft.,inches) 
.mg/dl; Triglycerides, __ .mgld l ;  LDL, 
HDL, __ .mg/dL  
Smoking? >20 cigarettes/day; 
Sedentary? Type of exercise 
Hypertension? Yes .; No 
Diabetes Mellitus? Yes ; No 
requiring 
Evidence of AtherosclQrosi~ 
.mg/dl; 
Carotid disease? 
Peripheral vascular disease? 
Other vascular disease? 
Coronary disease? 
<20 cigarettes/day; former; never  
; Number of times per week 
; If yes, controlled; n o t  controlled 
; If yes, insulin requiring; non- insu l in  
present; absent 
present; absent 
present; absent 
Unstable angina; 
3VD 
__ .no  ischemia 
Prior coronary event? __MI ;  Stable angina; 
PTCA; CABG 
Angiographic results? 1VD; 2VD; 
Stress Test with/without perfusion imaging? ischemia; 
Left ventricular function? Normal; Mildly/moderately reduced; 
Severely reduced 
A trial; VT; Prior VF Dysrhythmias? 
Comorbid Conditions 
Likely to Limit Life 
cal work capacity and blood pressure response in addition to 
evidence for inducible ischemia. The presence, frequency and 
characteristics of arrhythmias at rest and during stress may 
have important prognostic significance. As defined by the 
clinical presentation and preliminary stratification, additional 
appropriate testing may include coronary angiography, stress 
echocardiography and other imaging techniques. In the future, 
new imaging techniques may allow screening for the presence 
of anatomic atherosclerosis in the asymptomatic but at-risk 
patient. 
Establ ishment of Risk  
In the patient with coronary artery disease, individual risk is 
influenced by multiple conditions other than conventional risk 
factors, including age, prior infarction, left ventricular dysfunc- 
tion, arrhythmias, other systemic onditions (including diabe- 
tes mellitus, cerebral or peripheral vascular disease, emphy- 
sema and additional comorbid states), as well as response to 
prior interventions. The risk of death, cardiovascular morbid- 
ity, and an undesirable quality of life cannot be quantified from 
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Risk Intervention Recommendations 
Smoking: 
Goal 
complete cessation 
Lipid management: 
Primary goal 
LDL<100 mg/dL 
Secondary goals 
HDL>35 mg/dL; 
TG <200 mg/dL. 
Physical activity: 
Minimum goal 
30 minutes 3 to 4 
times per week 
Strongly encourage patient and family to stop smoking. 
Provide counseling, nicotine replacement, and formal cessation programs as appropriate. 
Start AHA Step II Diet in all patients: -<30% fat, <7% saturated fat, <200 mg/dL cholesterol. 
Assess fasting lipid profile. In post-MI patients, lipid profile may take 4 to 6 weeks to stabilize. Add drug therapy 
according to the following guide: 
LDL<100 mg/dL 
No drug therapy 
LDL 100 to 130 mg/dL LDL>130 mg/dL 
Consider adding drug therapy to Add drug therapy to diet, 
diet, as follows: as follows: 
Suggested drug therapy 
TG <200 mg/dL TG 200 to 400 mg/dL TG >400 mg/dL 
Statin Statin Consider combined 
Resin Niacin drug therapy (niacin, 
Niacin fibrate, statin) 
If LDL goal not achieved, consider combination therapy. 
Assess risk, preferably with exercise test, to guide prescription. 
Encourage minimum of 30 to 60 minutes of moderate-intensity activity 3 or 4 times weekly (walking, jogging, cycling, or 
other aerobic activity) supplemented by an increase in daily lifestyle activities (eg, walking breaks at work, using 
stairs, gardening, household work). Maximum benefit 5 to 6 hours a week. 
Advise medically supervised programs for moderate- to high-risk patients. 
HDL<35 mg/dL 
Emphasize weight 
management and 
physical activity. 
Advise smoking 
cessation. 
If needed to achieve 
LDL goals, consider 
niacin, statin, fibrate. 
Weight management: Start intensive diet and appropriate physical activity intervention, as outlined above, in patients >120% of ideal weight 
for height. 
Particularly emphasize need for weight loss in patients with hypertension, elevated triglycerides, or elevated glucose levels. 
Antiplatelet agents/ Start aspirin 80 to 325 mg/d if not contraindicated. 
anticoagulants: Manage warfarin to international normalized ratio=2 to 3.5 for post-MI patients not able to take aspirin. 
ACE inhibitors Start early post-MI in stable high-risk patients (anterior MI, previous MI, Killip class II [$3 gallop, rales, radiographic CHF]). 
)ost-Ml: Continue indefinitely for all with LV dysfunction (ejection fraction-<4O) or symptoms of failure. 
Use as needed to manage blood pressure or symptoms in all other patients. 
Beta-blockers: Start in high-risk post-MI patients (arrhythmia, LV dysfunction, inducible ischemia) at 5 to 28 days. Continue 6 months 
minimum. Observe usual contraindications. 
Use as needed to manage angina rhythm or blood pressure in all other patients. 
Estrogens: Consider estrogen replacement in all postmenopausal women. 
Individualize recommendation consistent with other health risks. 
Blood pressure Initiate lifestyle modification--weight control, physical activity, alcohol moderation, and moderate sodium restriction--in 
control: all patients with blood pressure>140 mm Hg systolic or 90 mm Hg diastolic. 
Goal Add blood pressure medication, individualized to other patient requirements and characteristics (ie, age, race, need for 
<140/90 mm Hg drugs with specific benefits) if blood pressure is not less than 140 mm Hg systolic or 90 mm Hg diastolic in 3 months 
or if init ial blood pressure is >160 mm Hg systolic or 100 mm Hg diastolic. 
Figure 2. Guide to comprehensive risk reduction for patients with 
coronary and other vascular disease. ACE = angiotensin-converting 
enzyme; AHA = American Heart Association; LV = left ventricular; 
TG = triglycerides; other abbreviations a in Figure 1. Reprinted with 
permission from Smith et al. (24). 
epidemiologic data alone with a precision sufficient to manage 
the individual patient. 
After an initial comprehensive evaluation, it is possible to 
assign a relative hazard as a baseline to develop an appropriate 
management strategy. The stroke and cardiac event risk factor 
prediction charts (see tables in Task Force 5), based on the 
Framingham Heart Study (23) of initially normal persons, is 
helpful, but not specific for the patient with coronary disease. 
Every patient who has had a cardiac event is at increased risk 
and deserving of assessment and management. Other factors 
listed previously must be integrated by the physician to provide 
a more realistic general prognosis (see Tables 5 to 8 and Figure 
3 in Task Force 5). 
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Figure 3. Guide to lipid management in 
patients with established cardiovascular dis- 
ease. *Lipoprotein analysis should be per- 
formed when the patient isnot in the recov- 
ery phase from an acute coronary or other 
medical event that would lower the usual low 
density lipoprotein cholesterol (LDL) levels. 
"Uf the first two low density lipoprotein cho- 
lesterol test results differ by >30 mg/dl 
(0.7 retool/liter), a third test should be ob- 
tained within 1 to 8 weeks and the average 
value of the three tests used. CHD = coro- 
nary heart disease. Reprinted with permis- 
sion from reference 30. 
Lipoprotein Analysis" After Fasting for 9 to 12 h 
Average of Two Measurements 
1 to 8 wk Apartt 
I 
Optimal LDL Cholesterol I 
_<100 mg/dL (2.6 mmol/L) f 
Higher Than Optimal LDL Cholesterol ] 
>100 mg/dL (2.6 mmol/L) tt 
I Individualize Instruction on Diet and Physical Activity Level Repeat Lipoprotein Analysis Annually 
Do Clinical Evaluation (History, 
Physical Examination, and 
Laboratory Tests) 
Evaluate for Secondary Causes 
(When Indicated) 
Evaluate for Familial Disorders 
(When Indicated) 
Consider Influences of Age, Sex, 
and Other CHD Risk Factors 
Initiate Therapy 
As discussed in Task Force 6, risk factor modification is
most cost effective and most efficient in patients with coronary 
disease, less so for patients with multiple severe risk factor 
abnormalities. Younger patients with mild angina, small in- 
farcts, as well as those who previously have undergone r vas- 
cularization, are most appropriate for efforts to reduce and 
improve adverse risk characteristics. Less favorable outcomes 
are to be expected in the elderly, patients with extensive 
irreversible cardiac damage or those with other organ system 
damage. 
Ongoing Care 
Initially, several physician visits may be necessary to estab- 
lish an optimal management strategy, monitor esponses and 
adjust subsequent treatment. Implementation a d mainte- 
nance of longer term care in conjunction with the primary care 
physician usually is appropriate, with follow-up by the cardio- 
vascular specialist for unanticipated changes in clinical events 
or further guidance in overall management. Data concerning 
blood pressure, body weight, lipid and glucose values hould be 
reviewed at regular intervals (annually or semiannually). It is 
essential that the patient recognize the overall nature of the 
plan, the need for a team approach and his or her essential and 
long-term role in its accomplishment. Management is a life- 
time process, as in patients with a variety of other chronic 
diseases. A continuum of reliable information relative to the 
initial level of risk and the efficacy of interventions in the 
modification of risk is essential. An appropriate lifetime flow- 
chart is a simple task with current computer technology and 
can function as a valuable motivator for both patient and 
physician. 
Management Strategies 
A detailed and comprehensive discussion of management 
strategies i outside the scope of this task force report. Several 
carefully considered published recommendations provide use- 
ful guidelines. General guidelines from the American Heart 
Association and endorsed by the American College of Cardi- 
ology are presented in Figure 2 (24,25). 
Brief comments on the risk factors designated category I 
(Task Force 3) follow: 
Smoking. Other than for those addicted, cigarette smoking 
is without redeeming social value in the population at large and 
is the single most obvious and important risk factor for 
coronary heart and vascular disease (26). It must be eliminated 
in the management of all patients at high risk for or with 
evident coronary artery disease. Increased taxation on the 
product, restriction of smoking in communal environments and 
other policy level inhibitors of smoking continue to confer 
significant benefits to patients with coronary disease and to the 
general population. 
Dietary regulation. For many years diet modification, in 
particular, reduction in the consumption of animal fat, has 
been a cornerstone ofcholesterol control. Over the years, the 
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Life-Style Modifications: 
Weight reduction 
Moderation of alcohol intake 
Regular physical activity 
Reduction of sodium intake 
Smoking cessation 
I 
Inadequate Response* 
Continue Life-Style Modifications 
Initial Pharmacologic Selection: 
Diuretics or beta-blockers are preferred because a reduction in 
morbidity and mortality has been demonstrated 
ACE inhibitors, calcium antagonists, alphacreceptor blockers 
and the alpha-beta blocker have not been tested nor shown to 
reduce morbidity and mortality 
I 
Inadequate Response* 
I 
Increase 
Drug Dose 
or  Substitute 
Another Drug 
or  
I 
Add a Second 
Agent From a 
Different Class 
I 
I 
Inadequate Response* 
Add a Second or Third Agent and/or 
Diuretic If Not Already Prescribed 
*Achieved goal blood pressure or patient making progress toward this goal. ACE = angiotensin-converting enzyme. 
Figure 4. Treatment algorithm. Reprinted with permission from reference 33. 
level of serum cholesterol in the U.S. population has declined, 
contributing to the reduction in cardiovascular disease mortal- 
ity rates. The objective of diet therapy is to reduce body weight 
and blood lipids to a level sufficient o reduce coronary risk. 
However, even under controlled clinical trial conditions (27), 
commonly recommended diets alone cause only a modest 
average fall in total and LDL cholesterol, with few subjects 
showing reductions exceeding 10%. While more rigorous 
vegetarian diets may result in satisfactory lipid lowering, they 
may cause considerable disruption in many homes so that a 
more acceptable solution is achieved by addition of lipid- 
lowering drugs (28). Low fat diets also facilitate the action of 
lipid-lowering drugs, and may favorably affect other important 
nonlipid mechanisms. Moreover, diets low in animal fat and 
high in fruits and vegetables will often reduce obesity, partic- 
ularly in older patients, and favorably influence blood pressure 
and triglyceride levels. Although several population studies 
indicate significant risk reduction associated with alcohol con- 
sumption, it would seem that initiation or encouragement of 
alcohol consumption has considerable risk for other adverse 
health and behavioral consequences (29). Users of alcohol, 
in moderation (one to two drinks per day), should not be 
discouraged. 
Serum lipids. In any patient who has sustained a coronary 
event, it should be suspected that the preexisting specific lipid 
levels are excessive (or deficient for HDL) for that patient and 
must be altered (Fig. 3) (30,31). Multiple studies with angio- 
graphic end points have shown the early and dramatic benefit 
of reduction of LDL cholesterol to under 100 mg/dl (21). 
Hence, virtually all coronary patients are candidates for lipid 
reduction. If dietary modification is insufficient, several drug 
interventions to lower lipids are available. In each, it is 
essential for the management team to define the specific action 
of the drug and then follow the resulting change by charting. 
The HMG-CoA reductase inhibitor class of drugs are effective 
in lowering total and LDL cholesterol by approximately 30% 
and cause a modest increase in HDL cholesterol, and appear, 
currently, to be the drugs of choice (32). The results of the 
Scandinavian Simvastatin Survival Study (4S) trial could be 
generalized to male and female younger and older patients and 
those with high and low initial lipid levels. As a class, statins 
have not been associated with a high rate of serious adverse 
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BP measured on two 
different occasions 
DBP ->105 mm Hg 
and/or 
SBP ->180 mm Hg: 
Institute drug treatment 
and non-drug treatment 
/ 
DBP 90-105 mm Hg 1 
and/or 
SBP 140-180 mm Hg: 
Repeat BP measurements 
on at least 2 occasions 
over a period of 4 wk 
After 4 wk 
DBP 90-105 mm Hg 
and/or 
SBP 140-180 mm Hg: 
Institute non-drug treatment 
and monitor BP 
BP < 140-90 mm Hg: 
Further BP measurements at 
3-mo intervals for i yr 
On first BP measurement 
BP < 140/90 mm Hg 
• High total cardiovascular risk or BP levels near 
to cutoff levels: Repeat BP measurement at 1 yr 
intervals 
• Low total cardiovascular risk and lower BP levels: 
Repeat BP measurement at 3 yr intervals 
After first 3 mo 
DBP ->100 mm Hg or 
SBP 160-180 mm Hg with 
DBP ->95 mm Hg: 
Reinforce non-drug treatment 
and start drug treatment 
DBP 90-100 mm Hg and/or 
SBP 160-180 mm Hg and high 
total cardiovascular risk: 
Reinforce non-drug treatment 
and consider drug treatment 
DBP 90-95 mm Hg and/or 
SBP 140-160 mm Hg and low 
total cardiovascular risk: 
Reinforce non-drug treatment 
and monitor BP 
After second 3mo 
DBP 95-100 mm Hg 
and/or 
SBP 160-180 mm Hg: 
Continue non-drug treatment 
and start drug treatment 
DBP 90-95 mm Hg and/or 
SBP 140-160 mm Hg and high 
total cardiovascular risk: 
Continue non-drug treatment 
and consider drug treatment 
DBP 90-95 mm Hg and/or 
SBP 140-160 mm Hg and low 
total cardiovascular risk: 
Continue non-drug treatment 
and monitor BP 
symptoms, although there is a low incidence of hepatic dys- 
function and myocytolysis, particularly in the elderly. The 
resins colestipol and cholestyramine and the fibric acid deriv- 
ative gemfibrozil are effective in reducing coronary event rates, 
but they do not induce as great an LDL lowering, and their 
unpleasant characteristics impair compliance. Nicotinic acid 
facilitates the cholesterol lowering achieved by diet and raises 
HDL, but also has unpleasant side effects. Probucol has been 
shown to not affect outcome, may prolong the QT interval and 
should be used in patients with low HDL values. Those 
pharmacologic nterventions that are associated with dose- 
related adverse symptoms are more likely to be met with 
noncompliance in a practice setting than in the conditions of 
controlled clinical trials. 
Blood pressure. The Joint National Committee (JNC-V) 
report on hypertension recommends that cuff blood pressure 
values, which correctly obtained and exceeding 140 mm Hg 
systolic and 90 mrn Hg diastolic (rest), deserve attention, in 
particular in the patient with coronary disease (33). A treat- 
ment algorithm and a practical guide are presented in Figures 
4 and 5. A comprehensive t am approach, with regular follow- 
up, offers the ideal circumstance for ensuring comPliance in 
effective drug therapy. 
Aspirin. Aspirin in low dose has proven benefit in all-cause 
mortality and in coronary event incidence (25). It is effective, 
inexpensive and should be part of the management of every 
patient at coronary risk, other than those with specific contra- 
indications. The role of warfarin sodium (Coumadin), heparin 
and newer antithrombotic and anticoagulants remains to be 
defined. 
Activity. Although sedentary life-style appears to have an 
adverse ffect in all persons, the long-term benefit of formal 
Figure 5. Guide to blood pressure (BP) management. Total cardio- 
vascular risk should be assessed first and the major components ofrisk 
identified. If 10-year coronary heart disease risk is >20% or will be 
>20% if projected to age 60, more intensive advice for all risk factors 
will be required. Clinical vascular disease will increase the risk to no 
more than 20% for most patients and to >40% for many. DBP = 
diastolic blood pressure; SBP = systolic blood pressure. Reprinted 
with permission. 
programs of exercise for the patient with coronary disease is 
not yet clear (34,35). Age, general conditioning, individual 
preference and motivation must play a part. Modest levels of 
physical activity offer benefit for weight reduction, and increase 
the sense of well-being. 
Stress. Behavior modification with regard to time manage- 
ment, urgency and hostility has demonstrated benefit (see Task 
Force 3). Further, counseling by the cardiovascular specialist 
may be appropriate arly after myocardial infarction as well as 
before and after revascularization. The patient must be as- 
sisted in dealing with the consequences of his/of her disease 
(36). 
Estrogen and progesterone. The temporal "advantage" 
enjoyed by women in regard to coronary disease is mediated in 
significant part by these hormones. In general, older women 
and those at above-average risk for coronary disease in partic- 
ular, will benefit from hormone therapy in a variety of ways 
(37). Definitive clinical trial data is required to define the 
benefit-risk relationship of postmenopausal estrogen adminis- 
tration in women with coronary disease. Those with a family 
history of breast cancer and at a younger age should not be 
encouraged to receive hormone therapy. 
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Other drugs. In patients with an acute myocardial infarc- 
tion, beta-blocking drugs reduce late mortality and reinfarction 
(25). Angiotensin-converting enzyme inhibitors decrease mor- 
tality in patients with left ventricular dysfunction and also 
decrease reinfarction rate. Use of these classes of drugs is a 
necessary component of optimal medical treatment of coro- 
nary artery disease. 
Summary  and  Recommendat ions  
Current medical management of atherosclerotic oronary 
artery disease often fails to reflect advances in current knowl- 
edge of risk factors and their effective modification. This 
failure results in an avoidable occurrence of death and disabil- 
ity and must be remedied. A strategy for optimal medical 
management of coronary disease requires lifetime attention 
and a cohesive team approach. 
The general principles of evaluation and management 
presented herein must be modified for each patient according 
to cardiac status, other medical conditions and specific cardiac 
risk characteristics. This mandates a standard of physician 
competence based on a knowledge and understanding of the 
underlying disturbances of vascular, metabolic and coagulative 
function, in addition to the conventional cardiologic compe- 
tencies. In each case, the strategy must include careful and 
continued documentation of the individual characteristics of 
the patient. Medical interventions must be individualized to 
limit risk, and to develop milestones to achieve these goals. If 
these goals are not met, then the treatment plan should be 
suitably modified. The trained specialist fills an essential role 
as consultant, coordinator and team leader of cardiac care. 
Effective treatment in patients with coronary disease and other 
at-risk patients can make efficient he consumption of available 
human and material resources. 
A healthy life-style in the general population, as well as in 
patients, is to be strongly encouraged. Designation of the term 
"prevention" as related to the problem of coronary heart 
disease is imprecise, inaccurate and confusing. The task at 
hand is the optimal medical treatment of atherosclerosis and 
should be so designated, as in the management of other 
chronic disease states. 
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Task Force 8. Organization of Preventive Cardiology Service 
THOMAS A. PEARSON,  MD, PHD, FACC, CHAIR,  PATRICK E. McBRIDE,  MD, MPH,  
NANCY HOUSTON MILLER,  RN, S IDNEY C. SMITH, JR., MD, FACC 
The expanding knowledge base regarding the pathophysiology, 
molecular biology, epidemiology and economic aspects of 
atherosclerotic cardiovascular disease provides a solid founda- 
tion for the development of guidelines for risk factor manage- 
ment. Randomized, controlled clinical trials have demonstrated 
the efficacy of a variety of interventions in the secondary 
prevention of coronary disease and in the primary prevention 
of disease in high risk individuals. The evidence and support of 
these interventions was felt sufficient o provide a consensus 
statement, endorsed by the American Heart Association and 
the American College of Cardiology, for the secondary pre- 
vention of coronary artery disease (1). 
However, the development ofa scientific rationale through 
basic and clinical studies often fails to influence clinical prac- 
tice. Convincing results of randomized clinical trials and widely 
disseminated guidelines often fall short of implementation 
(2-7). 
The existence of barriers to the implementation of risk 
reduction interventions appears obvious. Preventive services, 
including counseling, are provided less often than experts 
recommend and less frequently than patients and their physi- 
cians prefer (8). In a primary care setting, 75% of patients who 
smoke say they would attempt to stop smoking if their physi- 
cian advised them to do so, yet only 40% to 55% report that 
their physician provided such advice to them (9,10). Only 45% 
to 65% of patients with hypercholesterolemia hadevidence of 
treatment (3,11,12). The extent o which interventions recom- 
mended by the American College of Cardiology (1) are being 
carried out is poorly described. Table 1 shows estimates of the 
levels of risk factor management. These estimates deal only 
with initiation of any risk factor management; levels of ade- 
quacy of risk factor control could likely be much worse. 
Barriers that prevent hese efficacious and cost-effective inter- 
ventions from being deployed could be targetted as a way to 
correct deficiencies in levels of risk factor management. The 
objective of this task force report is to identify barriers within 
health care organizations which impede the provision of 
preventive services. Health care organizations under consider- 
ation range from primary care and cardiovascular specialty 
practices to hospitals, managed care organizations and third- 
party payors. Opportunities and strategies for these organiza- 
tions are then identified and evaluated as to their ability to 
effectively, feasibly and appropriately influence the provision 
of preventive cardiovascular services. Finally, a list of recom- 
mendations for organizations has been developed, based on 
the recognized needs of patients and providers and the pub- 
lished evidence supportive of the efficacy of specific strategies. 
Barriers to Implementation of Preventive 
Services: An Overview 
A variety of barriers to the successful implementation of
preventive services have been identified (Table 2). These 
include factors at the patient, provider, health care organiza- 
tion and community/societal levels (11,12). These different 
types of barriers might be considered sequential, in that any 
one barrier in the chain could result in a lack of provision of 
preventive service. 
Patient factors. A detailed discussion of patient factors is 
beyond the scope of this task force report. Physicians fre- 
quently perceive patients as not motivated or noncompliant, 
yet patients consistently report preventive services as a high 
priority for their health care and want physicians to provide 
life-style and prevention recommendations. Ironically, patients 
cite physicians's failure to order tests, give information or com- 
municate results as reasons not to request preventive services 
